# Vinorelbine Plus Capecitabine Versus Docetaxel Plus Capecitabine in Anthracycline-pretreated Women With Metastatic Breast Cancer

> **NCT01635465** · — · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Anthracycline-pretreated Metastatic Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01635465
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2016-11
- **Final completion:** 2016-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2015-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01635465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01635465, "Vinorelbine Plus Capecitabine Versus Docetaxel Plus Capecitabine in Anthracycline-pretreated Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01635465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*